How to Get Jatenzo in Maine

What Jatenzo Is and Why It Matters for Maine Patients

Jatenzo is the first FDA-approved oral testosterone undecanoate capsule for adult men with hypogonadism, approved in March 2019 as an alternative to injectable and topical testosterone formulations 1. For Maine patients who want to avoid weekly injections or daily gel application, an oral capsule taken twice daily with food offers a distinct practical advantage.

The key registration trial enrolled 166 hypogonadal men and demonstrated that 87% of participants achieved average testosterone concentrations within the normal range (300 to 1,100 ng/dL) at the 237 mg twice-daily dose 2. Swerdloff et al. published these findings in the Journal of Clinical Endocrinology & Metabolism, confirming that the lymphatic absorption pathway of Jatenzo reduces first-pass hepatic metabolism compared to older oral androgens like methyltestosterone 2. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy only after two separate morning serum total testosterone measurements confirm levels below 300 ng/dL 3.

Maine had an estimated 42,000 men aged 45 and older meeting clinical criteria for testosterone deficiency, based on prevalence data from the Massachusetts Male Aging Study showing that roughly 12% of men in this age bracket have biochemically low testosterone 4. Rural counties in Maine face particular barriers to endocrinology access, making telehealth a practical path to care.

Telehealth Prescribing of Jatenzo in Maine

Maine law permits telehealth prescribing of Schedule III controlled substances when a valid provider-patient relationship is established through a real-time audio-video encounter. This means a licensed physician, nurse practitioner, or physician assistant can evaluate, diagnose, and prescribe Jatenzo without requiring an in-person visit first 5.

The DEA's 2023 telemedicine rule extended pandemic-era flexibilities for Schedule III through V prescriptions via telehealth through the end of 2025, and subsequent rulemaking has maintained these provisions 5. Maine's Board of Licensure in Medicine aligns with this federal framework, requiring that telehealth encounters meet the same standard of care as in-person visits.

To start the process, a patient typically completes a health intake, provides recent lab work (or orders new labs), and schedules a video consultation. The prescriber reviews symptoms alongside two morning total testosterone readings below 300 ng/dL 3. If the clinical picture supports a diagnosis of male hypogonadism, the provider e-prescribes Jatenzo to a specialty or retail pharmacy licensed in Maine.

Telehealth has become especially significant for patients in Aroostook, Washington, and Piscataquis counties, where the nearest endocrinologist may be over 100 miles away. The American Urological Association notes that testosterone therapy initiation does not require subspecialist referral; primary care providers can manage most cases when following guideline-based protocols 6.

Lab Requirements Before Starting Jatenzo in Maine

Before any Maine provider prescribes Jatenzo, specific laboratory values must be documented. The Endocrine Society guideline mandates two morning fasting total testosterone levels below 300 ng/dL, drawn between 7:00 AM and 10:00 AM when diurnal secretion peaks 3.

A baseline laboratory panel should include:

• Total testosterone (two separate morning draws)
• Free testosterone or sex hormone-binding globulin (SHBG) to calculate bioavailable testosterone
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
• Complete blood count (CBC) with hematocrit, since testosterone therapy can raise red blood cell mass 7
• Prostate-specific antigen (PSA) in men over 40 per the AUA guideline 6
• Comprehensive metabolic panel including liver function tests and lipid profile

The FDA label for Jatenzo specifically warns about dose-dependent increases in systolic blood pressure: the registration trial showed mean increases of 3 to 5 mmHg at the 237 mg and 396 mg doses, respectively 1. Blood pressure monitoring is therefore part of the follow-up protocol. Hematocrit should be checked at 3 months, 6 months, and annually thereafter, with a threshold of 54% triggering dose reduction or temporary discontinuation 3.

Quest Diagnostics and Labcorp both operate draw sites across Maine, including Portland, Bangor, Lewiston, and Augusta. Many telehealth platforms provide pre-paid lab requisitions that patients can bring to any partnered collection site.

MaineCare and Private Insurance Coverage

MaineCare (Maine's Medicaid program) covers Jatenzo for male hypogonadism with prior authorization. The PA process requires documentation of two low testosterone lab values, clinical symptoms, and confirmation that the prescribing indication is FDA-approved hypogonadism rather than age-related decline alone 1.

Private insurers in Maine vary in their formulary placement of Jatenzo. Brand-name Jatenzo carries a wholesale acquisition cost of approximately $580 per month for the 237 mg twice-daily dose. Many commercial plans classify it as a non-preferred brand requiring step therapy through generic injectable testosterone cypionate or topical testosterone first. The FDA's Orange Book lists no approved generic for oral testosterone undecanoate as of May 2026 8.

Prior authorization documentation typically requires:

1. Two morning total testosterone levels <300 ng/dL
2. A signed statement from the prescriber documenting symptoms (fatigue, decreased libido, erectile dysfunction, loss of lean mass)
3. Clinical rationale for oral formulation over injectable or topical alternatives
4. Confirmation that the patient is not using testosterone for fertility, athletic performance, or cosmetic purposes

Turnaround time for MaineCare PA decisions is typically 24 to 72 hours. The Endocrine Society has stated that "insurance barriers to testosterone therapy remain a significant impediment to guideline-concordant care" 3, and Maine patients who receive a denial should request a peer-to-peer review between their prescriber and the plan's medical director.

503A Compounding Pharmacies in Maine

Maine-licensed 503A compounding pharmacies can prepare oral testosterone undecanoate capsules pursuant to a patient-specific prescription. These compounded versions are not AB-rated generics of Jatenzo; they are individually prepared formulations that follow USP compounding standards 9.

The FDA distinguishes between 503A pharmacies (patient-specific prescriptions, state-licensed) and 503B outsourcing facilities (batch production under federal cGMP oversight) 9. A 503A compounder in Maine can fill an oral testosterone undecanoate prescription at a lower cost than brand-name Jatenzo, often in the range of $90 to $180 per month depending on the dose and carrier oil used.

Patients considering compounded oral testosterone undecanoate should verify that their pharmacy holds a current Maine Board of Pharmacy compounding license and follows USP 795 standards for non-sterile compounding 10. The prescriber must write the prescription specifically for the compounded formulation; a Jatenzo-brand prescription cannot be automatically substituted with a compounded version.

One clinical consideration: the bioavailability of compounded oral testosterone undecanoate may differ from the proprietary Jatenzo formulation, which uses a self-emulsifying drug delivery system (SEDDS) designed for lymphatic absorption 2. Patients switching between brand and compounded versions should have testosterone levels rechecked 4 to 6 weeks after the change.

Who Can Prescribe Jatenzo in Maine

Three categories of licensed providers in Maine can prescribe Jatenzo. Each prescriber must hold an active DEA registration with Schedule III authority.

Physicians (MD/DO): Any Maine-licensed physician with a DEA registration can prescribe Jatenzo. Endocrinologists, urologists, and primary care physicians most commonly manage testosterone therapy. The AUA's 2018 guideline confirms that testosterone therapy initiation falls within the scope of primary care 6.

Nurse Practitioners (NP/CRNP): Maine grants full practice authority to nurse practitioners, meaning CRNPs can independently evaluate, diagnose, and prescribe Schedule III medications without a collaborative agreement with a physician 11. This is particularly relevant in rural Maine, where NPs serve as the primary prescriber in many community health centers.

Physician Assistants (PA): PAs in Maine prescribe under a supervisory agreement with a licensed physician. The supervision does not require the physician to be physically present for each encounter, but the agreement must be on file with the Maine Board of Licensure 6.

All three prescriber types must follow the same clinical protocol: confirm hypogonadism with two low morning testosterone values, rule out contraindications (polycythemia, untreated severe sleep apnea, breast or prostate cancer), and establish a monitoring plan 3.

Jatenzo Dosing, Titration, and Monitoring Protocol

The FDA-approved starting dose of Jatenzo is 237 mg taken orally twice daily with food 1. Food is not optional. The SEDDS formulation requires dietary fat for lymphatic absorption; taking Jatenzo on an empty stomach reduces bioavailability by approximately 50% based on pharmacokinetic data from the FDA review 1.

Dose titration follows a stepwise protocol:

• Check total testosterone at steady state (after at least 7 days on the current dose), drawn 3 to 5 hours post-morning dose
• If total testosterone <300 ng/dL, increase to 316 mg twice daily, then recheck
• If total testosterone remains <300 ng/dL at 316 mg, increase to 396 mg twice daily
• If total testosterone exceeds 1,100 ng/dL at any dose, decrease one step; the minimum dose is 158 mg twice daily

The 52-week open-label extension of the Swerdloff trial showed that 94% of patients maintained eugonadal testosterone levels at one year, with no serious hepatotoxicity signals 12. This long-term safety profile contrasts favorably with older oral androgens like methyltestosterone, which carried substantial hepatotoxicity risk 13.

Monitoring at 3 months, 6 months, and annually should include total testosterone, hematocrit, PSA (in men over 40), lipid panel, and blood pressure. The FDA label carries a boxed warning about the potential for blood pressure elevation, and providers should counsel patients about this risk 1.

Timeline: From First Consultation to Receiving Jatenzo in Maine

The typical sequence from first contact to capsules in hand spans 10 to 21 days, depending on insurance and pharmacy routing.

Days 1 to 3: Complete intake forms and schedule a telehealth or in-person visit. If labs are not already available, order two morning total testosterone draws along with the full baseline panel described above.

Days 4 to 7: Lab results return. The provider reviews them during the scheduled consultation, confirms diagnosis, and e-prescribes Jatenzo to the patient's chosen pharmacy.

Days 7 to 14: For patients requiring prior authorization, the prescriber's office submits documentation to the insurer. MaineCare PA decisions typically arrive within 24 to 72 hours. Commercial plans may take up to 14 business days, though most respond within 5 8.

Days 14 to 21: The specialty pharmacy fills and ships Jatenzo. Most specialty pharmacies offer overnight or two-day shipping to all Maine ZIP codes, including rural areas. Patients using a local retail pharmacy may pick up the prescription the same day the PA clears.

Patients who pay out of pocket or use a compounding pharmacy can often bypass the PA step entirely, reducing the total timeline to 7 to 10 days.

Transferring an Existing Jatenzo Prescription to Maine

Patients relocating to Maine from another state can transfer their Jatenzo prescription under DEA rules governing Schedule III interstate transfers. The receiving Maine pharmacy contacts the originating out-of-state pharmacy to verify the prescription, remaining refills, and prescriber information 14.

Because Jatenzo is Schedule III, it is eligible for prescription transfer between pharmacies. The key requirements are that both pharmacies are licensed in their respective states and that the prescriber holds an active DEA registration. Maine does not impose additional state-level restrictions on inbound controlled substance prescription transfers beyond federal requirements 14.

If the patient's original prescriber is not licensed in Maine, a new Maine-licensed provider must assume prescribing responsibility. A single telehealth visit with lab review is typically sufficient to establish the new provider-patient relationship and continue the existing regimen without interruption.